Abstract
Clinically silent adrenocortical adenomas are the most frequent abnormalities in the adrenal gland. In contrast, adrenocortical carcinoma is a rare tumor with an extremely poor prognosis. The factors responsible for the frequent occurrence of benign adrenocortical tumors on one hand and the rare malignant transformation on the other are not known. Several genetic alterations such as loss of imprinting or loss of heterozygosity of the 11p15 gene locus causing a strong IGF-II overexpression have been demonstrated in the majority of adrenocortical carcinomas. In addition to IGF-II overexpression, increased levels of the IGF-I-receptor and IGFBP-2 have been found in advanced human adrenocortical carcinomas, suggesting an important role for the IGF-system in adrenocortical carcinogenesis. IGFs are potent mitogens regulating growth and apoptosis through interaction with the IGF-I-receptor, and overexpression of the human IGF-I-receptor promotes ligand-dependent neoplastic transformation in a variety of different cell systems. It is evident, therefore, that high levels of IGF-II in combination with overexpression of the IGF-I-receptor can provide a significant growth advantage for adrenocortical carcinoma cells and thus contribute to the highly malignant phenotype of this rare type of cancer. Additionally, it has been shown that overexpression of IGFBP-2 can promote malignant transformation of Y1 mouse adrenocortical tumor cells through unknown IGF-independent mechanisms. As one possible mechanism, we have recently found altered expression of catalase in IGFBP-2-overexpressing tumor cells, thus implicating IGFBP-2 in influencing intracellular peroxide levels. However, since transgenic mice with IGF-II or IGFBP-2 overexpression in the adrenal gland do not show an increased frequency of adrenal tumors, IGF-II or IGFBP-2 may act as progression factors but not as initiation factors in adrenocortical tumorigenesis.
Key words
IGF-I - IGF-II - IGF-I-receptor - IGFBP - Adrenal - Tumorigenesis
References
-
1
Reincke M.
Mutations in adrenocortical tumors.
Horm Met Res.
1998;
30
447-455
-
2
Kjellmann M, Larsson C, Bäckdähl M.
Genetic background of adrenocortical tumor development.
World J Surg.
2001;
25
948-95
-
3
Weber M M, Kiess W, Beikler T, Simmler P, Reichel M, Adelmann B, Kessler U, Engelhardt D.
Identification and characterization of insulin-like growth factor I (IGF-I) and IGF-II/mannose-6-phosphate (IGF-II/M6P) receptors in bovine adrenal cells.
Eur J Endocrinol.
1994;
130
265-270
-
4
Weber M M, Simmler P, Fottner C, Engelhardt D.
Insulin-like growth factor II (IGF-II) is more potent than IGF-I in stimulating cortisol secretion from cultured bovine adrenocortical cells: Interaction with the IGF-I-receptor and IGF-binding proteins.
Endocrinology.
1995;
136
3714-3720
-
5 Weber M M, Fottner C, Engelhardt D. Adrenocortical and adrenomedullary cells. In: Bidley S (ed) Endocrine cell culture. Cambridge University Press 1998: 16-31
-
6
Fottner C, Engelhardt D, Weber M M.
Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF-I and, more potently, IGF-II preferentially enhance androgen biosynthesis through interaction with the IGF-I-receptor and IGF-binding proteins.
J Endocrinol.
1998;
158
409-417
-
7
Fottner C, Engelhardt D, Weber M M.
Characterization of Insulin-like growth factor binding proteins (IGFBPs) secreted by bovine adrenocortical cells in primary culture: Regulation by Insulin-like growth factors (IGFs) and adrenocorticotropin (ACTH).
Hormone and Metabolism Research.
1999;
31
203-208
-
8
Fottner C, Elmlinger M, Engelhardt D, Weber M M.
Identification and characterization of Insulin-like growth factor (IGF) binding protein-expression and -secretion by adult human adrenocortical cells: Differential regulation by IGFs and adrenocorticotropin.
Journal of Endocrinology.
2001;
168
465-474
-
9
Penhoat A, Rainey W E, Viard I, Saez J M.
Regulation of adrenal cell-differentiated functions by growth factors.
Horm Res.
1994;
42
39-43
-
10
Mesiano S, Mellon S H, Jaffe R B.
Mitogenic action, regulation, and localization of insulin-like growth factors in the human fetal adrenal gland.
J Clin Endocrinol Metab.
1993;
76
968-976
-
11
Voutilainen R, Miller W L.
Developmental and hormonal regulation of mRNAs for insulin-like growth factor II and steroidogenic enzymes in human fetal adrenals and gonads.
DNA.
1988;
7
9-15
-
12
Ilvesmäki V, Blum W F, Voutilainen R.
Insulin-like growth factor-II in human fetal adrenals: regulation by ACTH, protein kinase C and growth factors.
J Endocrinol.
1992;
137
533-42
-
13
Ilvesmäki V, Kahri A I, Miettinen P J, Voutilainen R.
Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas.
J Clin Endocrinol Metab.
1993;
77
852-858
-
14
Hesse V, Jahreis G, Schambach H, Vogel H, Vilser C, Seewald H, Börner A, Deichl A.
Insulin-like growth factor I correlations to changes of the hormonal status in puberty and age.
Exp Clin Endocrinol.
1994;
102
289-298
-
15
Glasscock G F, Hein A N, Millar J A, Hintz R L, Rosenfeld R G.
Effects of continuous infusion of insulin-like growth factor I and II, alone and in combination with thyroxine or growth hormone, on the neonatal hypophysectomized rat.
Endocrinology.
1992;
130
203-210
-
16
Rogler C E, Yang D, Rossetti L, Donohoe J, Alt E, Chang C E, Rosenfeld R, Neely K, Hintz R.
Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice.
J Biol Chem.
1994;
260
3779-13 784
-
17
Ward A, Bates P, Fisher R, Richardson L, Graham C F.
Disproportionate growth in mice with IGF-II transgenes.
Proc Natl Acad Sci USA.
1994;
91
10 365-10 369
-
18
Wilson D M, Thomas J A, Hamm T E, Wyche J, Hintz R L, Rosenfeld R G.
Transplantation of IGF-II secreting tumours into nude rodents.
Endocrinology.
1987;
120
1896-1901
-
19
Rainey W E, Parker C R, Rehmann K, Carr B R.
The adrenal genetic puzzle: how do fetal and adult pieces differ?.
Endocr Res.
2002;
28
611-622
-
20
Mesiano S, Jaffe R B.
Developmental and functional biology of the primate fetal adrenal cortex.
Endocr Rev.
1997;
18
378-403
-
21
Han V K, Lu F, Bassett N, Yang K P, Delhanty P J, Challis J R.
Insulin-like growth factor-II (IGF-II) messenger ribonucleic acid is expressed in steroidogenic cells of the developing ovine adrenal gland: evidence of an autocrine/paracrine role for IGF-II.
Endocrinology.
1992;
131
3100-3109
-
22
Voutilainen R, Miller W L.
Coordinate tropic hormone regulation of mRNAs for insulin-like growth factor II and the cholesterol side-chain-cleavage enzyme, P450ssc, in human steroidogenic tissues.
Proc Natl Acad Sci USA.
1987;
84
1590-1594
-
23
l' Allemand D, Penhoat A, Blum W, Saez J M.
Is there a local IGF-system in human adrenocortical cells?.
Mol Cell Endocrinol.
1998;
140
169-73
-
24
Weber M M, Kiess W, Beikler T, Simmler P, Reichel M, Adelmann B, Kessler U, Engelhardt D.
Identification and characterization of insulin-like growth factor I (IGF-I) and IGF-II/mannose-6-phosphate (IGF-II/M6P) receptors in adrenal cells.
Eur J Endocrinol.
1994;
130
265-270
-
25
Penhoat A, Rainey W E, Viard I, Saez J M.
Regulation of adrenal cell-differentiated functions by growth factors.
Hormone Research.
1994;
42
39-43
-
26
Weber M M, Auernhammer C J, Kiess W, Engelhardt D.
Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands.
Eur J Endocrinol.
1997;
136
296-303
-
27
Kamio T, Shigematsu K, Kawai K, Tsuchiyama H.
Immunoreactivity and receptor expression of Insulin-like growth factor I and insulin in human adrenal tumors.
Am J Pathol.
1991;
138
83-91
-
28
Logié A, Boulle N, Gaston V, Perin L, Bourdou P, Le Bouc Y.
Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line.
J Mol Endocrinol.
1999;
23
23-32
-
29
LeRoith D, Roberts C T.
The Insulin-like growth factor system and cancer.
Cancer letters.
2003;
195
127-137
-
30
Grimberg A, Cohen P.
Role of Insulin-like growth factors and their binding proteins in growth control and carcinogenesis.
J Cell Physiol.
2000;
183
1-9
-
31
Ilvesmäki V, Blum W F, Voutilainen R.
Insulin-like growth factor binding proteins in the human adrenal gland.
Mol Cell Endocrinol.
1992;
97
71-79
-
32
Fottner C, Spöttl G, Engelhardt D, Weber M M.
The divergent effect of insulin-like growth factor binding protein (IGFBP)-1 on the steroidogenic effect of IGF-I and IGF-II in bovine adrenocortical cells is not due to its phosphorylation status.
Growth Hormone and IGF-Research.
2003;
13
219
-
33
Weber M M, Fottner C, Wolf E.
The role of the insulin-like growth factor (IGF) system in adrenocortical tumorigenesis.
Eur J Clin Invest.
2000;
30
69-75
-
34
Conlon M A, Tomas F M, Owens P, Wallace J C, Howarth G S, Ballard F J.
Long R3 Insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig.
J Endocrinol.
1995;
146
247-253
-
35
Hoeflich A, Weber M M, Fisch T, Nedbal S, Fottner C, Elmlinger M W, Wanke R, Wolf E.
Insulin-Like Growth Factor-Binding Protein-2 (IGFBP-2) separates hypertrophic and hyperplastic effects of Growth Hormone (GH)/IGF-I excess on adrenocortical cells in vivo.
FASEB-J.
2002;
16
1721-1731
-
36
Edgren M, Eriksson B, Wilander E, Westlin J E, Nilsson S, Öberg K.
Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas.
Anticancer Res.
1997;
17
1303-1310
-
37
de Fraipont F D, Le Moigne G, Defaye G, El Atifi M, Berger F, Houlgatte R, Gicquel C, Plouin P F, Bertagna X, Chabre O, Feige J J.
Transcription profiling of benign and malignant adrenal tumors by cDNA macro-array analysis.
Endocr Res.
2002;
28
785-786
-
38
Schneid H, Seurin D, Noguiez P, Le Bouc Y.
Abnormalities of insulin-like growth factor (IGF-I and IGF-II) genes in human tumor tissue.
Growth Regulation.
1992;
2
45-54
-
39
Gicquel C, Bertagna X, Le Bouc Y.
Recent advances in the pathogenesis of adrenocortical tumours.
Eur J Endocrinol.
1995;
133
133-144
-
40
Faical S, Maciel R MB, Nose-Alberti V, Santos M C, Kater C E.
Immunodetection of Insulin-like growth factor I (IGF-I) in normal and pathological adrenocortical tissue.
Endocrine Pathology.
1998;
9
63-70
-
41
Ilvesmaki V, Kahri A I, Miettinen P J, Voutilainen R.
Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas.
J Clin Endocrinol Metab.
1993;
77
852-858
-
42
Giordano T J, Thomas D G, Kuick R, Lizyness M, Misek D E, Smith A L, Sanders D, Aljundi R T, Gauger P G, Thompson N W, Taylor J MG, Hanash S.
Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.
Am J Pathol.
2003;
162
521-531
-
43
Erickson L A, Jin L, Sebo T J, Lohse C, Pankratz V S, Kendrick M L, van Heerden J A, Thompson G B, Gran C S, Lloyd R V.
Pathological features and expression of Insulin-like growth factor-2 in adrenocortical neoplasms.
Endocr Pathol.
2001;
12
429-435
-
44
Boulle N, Logié A, Gicquel C, Perin L, Le Bouc Y.
Increased levels of Insulin-like growth factor II (IGF-II) and IGF-Binding Protein-2 are associated with malignancy in sporadic adrenocortical tumors.
J Clin Endocrinol Metab.
1998;
83
1713-1720
-
45
Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos J M, Schlumberger M, Plouin P F, Luton J P, Le Bouc Y.
Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors.
Cancer Res.
2001;
61
6762-6767
-
46
Yano T, Linehan M, Anglard P.
Genetic changes in human adrenocortical carcinomas.
J Natl Cancer Inst.
1989;
81
518-523
-
47
Le Bouc Y, Noguiez P, Sondermeijer P, Dreyer D, Girard F, Binoux M.
A new 5′-non-coding region for human placental IGF-II mRNA expression.
FEBS Lett.
1987;
222
181-185
-
48
Wolf E, Kramer R, Blum W F, Föll J, Brem G.
Consequences of postnatally elevated insulin-like growth factor-II in transgenic mice: endocrine changes and effects on body and organ growth.
Endocrinology.
1994;
135
1877-1886
-
49
Weber M M, Fottner C, Schmidt P, Brodowski K MH, Gittner K, Lahm H, Engelhardt D, Wolf E.
Postnatal overexpression of IGF-II in transgenic mice is associated with adrenocortical hyperplasia and enhanced steroidogenesis.
Endocrinology.
1999;
140
1537-1543
-
50
Wolf E, Hoeflich A, Lahm H.
What is the function of IGF-II in postnatal life? Answers from transgenic mouse models.
Growth Horm IGF Res.
1998;
8
185-193
-
51
Kirschner L S.
Signaling pathways in adrenocortical cancer.
Ann N Y Acad Sci.
2002;
58
222-239
-
52
Toretsky J A, Helman L J.
Involvement of IGF-II in human cancer.
J Endocrinol.
1996;
149
367-372
-
53
Wilkin F, Gagné N, Paquette J, Oligny L L, Deal C.
Pediatric adrenocortical tumors: molecular events leading to Insulin-like growth factor II gene overexpression.
J Clin Endocrinol Metab.
2000;
85
2048-2056
-
54
Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton J P, Girard F. et al .
Rearrangements at the 11p15 locus and over expression of insulin-like growth factor-II gene in sporadic adrenocortical tumors.
J Clin Endocrinol Metab.
1994;
78
1444-53
-
55
Gicquel C, Raffin-Sanson M L, Gaston V, Bertagna X, Plouin P F, Schlumberger M, Louvel A, Luton J P, Le Bouc Y.
Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: Study on a series of 82 tumors.
J Clin Endocrinol Metab.
1997;
82
2559-2565
-
56
Liu J, Kahri A I, Heikkilä P, Ilvesmäki V, Voutilainen R.
H19 and insulin-like growth factor-II gene expression in adrenal tumors and cultured adrenal cells.
J Clin Endocrinol Metab.
1995;
80
492-496
-
57
Bourcigaux N, Gaston V, Logie A, Bertagna X, Le Bouc Y, Gicquel C.
High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors.
J Clin Endocrinol Metab.
2000;
85
322-330
-
58
Schneid H, Seurin D, Vasquez M-P, Gourmelen M, Cabrol S, Le Bouc Y.
Parental allele specific methylation of the human insulin-like growth factor-II gene and Beckwith Wiedemann syndrome.
J Med Genet.
1993;
30
353-362
-
59
Paquette J, Giannoukakis N, Polychronakos C, Vafiadis P, Deal C.
The INS 59 variable number of tandem repeats is associated with IGF2 expression in humans.
J Biol Chem.
1998;
273
14 158-14 164
-
60
Yano T, Linehan M, Anglard P, Lerman M I, Daniel L N, Stein C A.
Genetic changes in human adrenocortical carcinomas.
J Natl Cancer Inst.
1989;
81
518-523
-
61
Thibout H, Martinerie C, Créminon C, Godeau F, Boudou P, Le Bouc Y, Laurent M.
Characterization of Human NOV in Biological Fluids: An Enzyme Immunoassay for the Quantification of Human NOV in Sera from Patients with Diseases of the Adrenal Gland and of the Nervous System.
J Clin Endocrinol Metab.
2003;
88
327-336
-
62
Martinerie C, Gicquel C, Louvel A, Laurent M, Schofield P N, Le Bouc Y.
Altered Expression of novH Is Associated with Human Adrenocortical Tumorigenesis.
J Clin Endocrinol Metab.
2001;
86
3929-3940
-
63
Weber M M, Fottner C, Liu S B, Jung M C, Engelhardt D, Baretton G B.
Overexpression of the insulin-like growth factor I receptor in human colon carcinomas.
Cancer.
2002;
95
2086-2095
-
64
Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even P C, Cervera P, Le Bouc Y.
IGF-I-receptor regulates lifespan and rsistance to oxidative stress in mice.
Nature.
2003;
421
182-187
-
65
Lithgow G, Gill M S.
Cost-free longevity in mice?.
Nature.
2003;
421
125-127
-
66
Rubin R, Baserga R.
Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity.
Lab Invest.
1995;
73
311-331
-
67
Werner H, Shalita-Chesner M, Abramovitch S, Idelman G, Shaharabani-Gargir L, Glaser T.
Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer.
Mol Genet Metab.
2000;
71
315-320
-
68
Werner H, Le Roith D.
New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia.
Cell Mol Life Sci.
2000;
57
932-942
-
69
Neuberg M, Buckbinder L, Seizinger B, Kley N.
The p53/IGF-1 receptor axis in the regulation of programmed cell death.
Endocrine.
1997;
7
107-109
-
70
Makos Wales B, Biel M, El Deiry W.
p53 activates expression of HIC-1, a new dandidate tumor suppressor gene on 17p13.3.
Nat Med.
1995;
1
570-582
-
71
Werner H, Karnieli E, Rauscher F J, LeRoith D.
Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.
Proc Natl Acad Sci USA.
1996;
93
8318-8323
-
72
Girnita L, Girnita A, Brodin B.
Increased expression of insulin-like growth factor I receptor in malignant cells expressing abberant p53: functional impact.
Cancer Res.
2000;
60
5278-5283
-
73
Reincke M, Karl M, Travis W, Mastorakos G, Allolio B, Linehan H, Chrousos G.
p53 mutations in human adrenocortical neoplasms: immunhistochemical and molecular studies.
J Clin Endocrinol Metab.
1994;
78
790-796
-
74
Hoeflich A, Yang Y, Rascher W. et al .
Coordinate expression of insulin-like growth factor II (IGF-II) and IGF-II/mannose-6-phosphate receptor mRNA during differentiation of human colon carcinoma cells (caco-2).
Eur J Endocrinol.
1996;
135
49-59
-
75
O'Gorman D B, Costello M, Weiss J, Firth S M, Scott C D.
Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells.
Cancer Res.
1999;
59
5692-5694
-
76
Souza R F, Wang S, Thakar M, Smolinski K N, Yin J, Zou T T, Kong D, Abraham J M, Toretsky J A, Meltzer S J.
Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells.
Oncogene.
1999;
18
4063-4068
-
77
Leboulleux S, Gaston V, Boulle N, Le Bouc Y, Gicquel C.
Loss of heterozygosity at the mannose 6-phosphate/insulin-like growth factor 2 receptor locus: a frequent but late event in adrenocortical tumorigenesis.
Eur J Endocrinol.
2001;
144
163-168
-
78
Boulle N, Baudin E, Gicquel C, Logié A, Bertherat J, Penfornis A, Bertagna X, Luton J P, Schlumberger M, Le Bouc Y.
Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors.
Eur J Endocrinol.
2001;
144
29-36
-
79
Hoeflich A, Reisinger E, Lahm H, Kiess W, Blum W F, Kolb H J, Weber M M, Wolf E.
Insulin-like growth factor binding protein 2 in tumorigenesis: protector or promoter?.
Cancer Res.
2001;
61
8601-8610
-
80
Hoeflich A, Nedbal S, Blum W F, Erhard M, Lahm H, Brehm G, Kolb H J, Wanke R, Wolf E.
Growth inhibition in giant growth hormone transgenic mice by overexpression of Insulin-Like Growth Factor-Binding Protein-2 (IGFBP-2).
Endocrinology.
2001;
142
1889-1898
-
81
Hoeflich A, Fettscher O, Lahm H, Blum W F, Kolb H J, Engelhardt D, Wolf E, Weber M M.
Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells.
Cancer Res.
2000;
60
834-838
-
82
Hoeflich A, Fettscher O, Preta G, Lahm H, Kolb H J, Wolf E, Weber M M.
Increased Enzyme Activities of Catalase in Tumor Cells Overexpressing IGFBP-2.
Horm Metab Res.
2003;
35
816-821
-
83
Bernard M H, Sidhu S, Berger N, Peix J L, Marsh D, Robinson B, Gaston V, Le Bouc Y, Gicquel C.
A case report in favor of a multistep adrenocortical tumorigenesis.
J Clin Endocrinol Metab.
2003;
88
998-1001
-
84
Khandwala H M, McCutcheon I E, Flyvbjerg A, Friend K E.
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.
Endocrine Reviews.
2000;
21
215-244
-
85
Pham-Huu-Trung M T, Villette J M, Bogyo A, Duclos J M, Fiet J, Binoux M.
Effects of insulin-like growth factor-I (IGF-I) on enzymatic activity in human adrenocortical cells. Interactions with ACTH.
J Steroid Biochem Molec Biol.
1991;
39
903-909
-
86
Naseeruddin S A, Hornsby P J.
Regulation of 11β-17α-hydroxylases in cultured bovine adrenocortical cells: 3′,5′-cyclic adenosine monophosphate, insulin-like growth factor-I, and activators of protein kinase C.
Endocrinology.
1990;
127
1673-1681
-
87
Penhoat A, Jaillard C, Saez J M.
Synergistic effects of corticotropin and insulin-like growth factor I on corticotropin receptors and corticotropin responsiveness in cultured bovine adrenocortical cells.
Biochem Biophys Res Commun.
1989;
165
355-359
-
88
Pham-Huu-Trung M T, Binoux M.
Insulin-like growth factor-I (IGF-I) induces cortisol production in bovine adrenocortical cells in primary culture.
J Steroid Biochem.
1990;
36
583-588
-
89
Fottner C, Matezki G, Engelhardt D, Weber M M.
The divergent effect of insulin-like growth factor binding protein (IGFBP) - 1 on IGF induced cortisol secretion in bovine adrenocortical cells is not due to different affinities of the IGFBP-1-phosphorylation isoforms for IGFs.
Exp Clin Endocrinol & Diabetes.
2001;
109 (Suppl 1)
152
-
90
Kristiansen S B, Endoh A, Casson P R, Buster J E, Hornsby P J.
Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells.
Steroids.
1997;
62
258-265
-
91
Naaman E, Chatelain P, Saez J M, Durand P.
In vitro effect of insulin and insulin-like growth factor-I on cell multiplication and adrenocorticotropin responsiveness of fetal adrenal cells.
Biol Reprod.
1989;
40
570-577
Prof. Dr. med. M. M. Weber
Schwerpunkt Endokrinologie und Stoffwechselerkrankungen · I. Medizinische Klinik und Poliklinik · Johannes Gutenberg Universität Mainz
Langenbeckstraße 1 · 55131 Mainz · Germany
Telefon: +49 (6131) 177260
Fax: +49 (6131) 175608
eMail: MMWeber@uni-mainz.de
